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Identity 
Other names: FAD; FAD2; FACD; FANCD 
HGNC (Hugo): FANCD2 
Location: 3p25-26 
Local order: not far from XPC, in 3p25. 
 
Probe(s) - Courtesy Mariano Rocchi, Resources for Molecular 
Cytogenetics. 
DNA/RNA 
Description 
44 exons; 4356 bp open reading frame; the first exon is 
non-coding. 
Protein 
Description 
1452 amino acids; 155 kDa (FANCD2-S isoform, for 
short), and 162 kDa (FANCD2-L isoform, for long) by 
ubiquitin addition. 
Expression 
Weak. 
Localisation 
Nucleus. 
Function 
The FA complex is comprised of: FANCA, FANCC, 
FANCE, FANCF, and FANCG; this complex is only 
found in the nucleus. 
FANCA and FANCG form a complex in the 
cytoplasm, through a N-term FANCA (involving the 
nuclear localization signal) - FANCG interaction; 
FANCC join the complex; phosphorylation of FANCA 
would induce its translocation into the nucleus.This FA 
complex translocates into the nucleus, where FANCE 
and FANCF are present; FANCE and FANCF join the 
complex. The FA complex subsequently interacts with 
FANCD2 by monoubiquitination of FANCD2 during S 
phase or following DNA damage. Activated 
(ubiquinated ) FANCD2 (i.e. FANCD2-L), downstream 
in the FA pathway, will then interact with other 
proteins involved in DNA repair, possibly BRCA1; 
after DNA repair, FANCD2 return to the non-
ubiquinated form (FANCD2-S). 
FANCD2co-localizes with BRCA1 in DNA damaged-
induced loci and in the synaptonemal complex of 
meotic chromosomes as well. 
Homology 
Significant homologies can be found with proteins 
from various species. 
Implicated in 
Fanconi anaemia (FA) 
FANCD2 is implicated in the FA complementation 
group D, a heterogeneous group, with at least 2 genes: 
FANCD2, and a yet undiscovered FANCD1. FA 
complementation group D represents about 1% of FA 
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cases. In FA complementation group D patients, the FA 
complex is normal, in contrast with results found in 
group A, B (with a yet unknown gene), C, E, F, and G 
patients. 
Disease 
Fanconi anaemia is a chromosome instability 
syndrome/cancer prone disease (at risk of leukaemia 
and squamous cell carcinoma). 
Prognosis 
Fanconi anaemia's prognosis is poor; mean survival is 
20 years: patients die of bone marrow failure 
(infections, haemorrhages), leukaemia, or solid cancer. 
It has recently been shown that significant phenotypic 
differences were found between the various 
complementation groups. Patients from the rare groups 
FA-D, FA-E, and FA-F had somatic abnormalities 
more frequently. 
Cytogenetics 
Spontaneously enhanced chromatid-type aberrations 
(breaks, gaps, interchanges; increased rate of breaks 
compared to control, when induced by specific 
clastogens known as DNA cross-linking agents (e.g. 
mitomycin C, diepoxybutane). 
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